S&P Futures
6,004.25 -2.25 (-0.04%) Dow Futures
44,820.00 -6.00 (-0.01%) Nasdaq Futures
20,889.75 +9.50 (+0.05%) Russell 2000 Futures
2,436.60 -14.40 (-0.59%) Crude Oil
69.12 +0.18 (+0.26%) Gold
2,617.00 -1.50 (-0.06%)
AstraZeneca PLC (AZN)
After hours:
| Previous Close | 65.63 |
| Open | 65.92 |
| Bid | 66.34 x 400 |
| Ask | 66.46 x 400 |
| Day's Range | 65.86 - 66.57 |
| 52 Week Range | 60.47 - 87.68 |
| Volume | |
| Avg. Volume | 5,387,055 |
| Market Cap | 205.881B |
| Beta (5Y Monthly) | 0.18 |
| PE Ratio (TTM) | 31.92 |
| EPS (TTM) | 2.08 |
| Earnings Date | Feb 06, 2025 |
| Forward Dividend & Yield | 1.49 (2.24%) |
| Ex-Dividend Date | Aug 09, 2024 |
| 1y Target Est | 88.27 |
Insider MonkeyAstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest In AZN?
We recently published a list of the 10 Most Profitable European Stocks to Invest In. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other profitable European stocks to buy. How Could Trump’s Trade Tariffs Impact Europe? After the U.S. Presidential elections, the global economies might […]
Business WireTRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
WILMINGTON, Del., November 25, 2024--Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer
